
Kuva Labs launches $4/share tender offer to acquire Lisata Therapeutics, plus potential $3/share milestone payments.
Kuva Labs has initiated a tender offer to buy all outstanding shares of Lisata Therapeutics at $4.00 per share in cash, with an additional contingent value right (CVR) offering up to $3.00 per share if certain clinical milestones are met. The Lisata ...

